Treatment options in patients with metastatic gastric cancer: Current status and future perspectives

doi:10.3748/wjg.v20.i14.3905

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 14

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9932)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

652

WORD

337

HTML

6708

Tables (1-3)

206

Sum=7903

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

988

Download

1041

Sum=2029

Apr 14, 2014 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (67)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Apr 14, 2014; 20(14): 3905-3915
Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.3905

Table 3 Second-line chemotherapy trials in patients with advanced gastric cancer

Ref.	Regimen	No. of patients	Response rate	Median PFS/TTP and OS (mo)
Kang et al[82]	Docetaxel or irinotecan + BSC vs BSC	202	-	TTP, NA; OS, 5.3 vs 3.8
Thuss-Patience et al[83]	Irinotecan vs BSC	40	44% vs 5%	PFS, 2.6 vs NA; OS, 4.0 vs 2.4
Ford et al[84]	Docetaxel + BSC vs BSC	168	7% vs NA	PFS, 5.6 vs 5.0; OS, 5.2 vs 3.6
Shimada et al[85]	Irinotecan + cisplatin vs irinotecan	130	21.9% vs 16.4%	PFS, 4.17 vs 3.03; OS, NA

BSC: Best supportive care; NA: Not applicable; PFS: Progression-free survival; OS: Overall survival; TTP: Time-to progression.

Citation: Bilici A. Treatment options in patients with metastatic gastric cancer: Current status and future perspectives. World J Gastroenterol 2014; 20(14): 3905-3915
URL: https://www.wjgnet.com/1007-9327/full/v20/i14/3905.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i14.3905